BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. In 2008, approximately 37,680 people will be diagnosed with pancreatic cancer and 34,290 will die of this disease. METHODS: The authors reviewed the literature on treatment of pancreatic cancer with an emphasis on studies conducted in the US Oncology Research (USOR) Network. RESULTS: Although much research has been conducted to develop improved systemic therapies of pancreatic cancer, gemcitabine as a single agent remains the current standard of care. Combinations with other chemotherapeutic drugs or biological agents have resulted in limited improvement. CONCLUSIONS: Despite aggressive efforts to improve treatment for patients with pancreatic cancer, limited progress has been made. It is hoped that new studies being planned and conducted will improve outcomes for patients with this disease.
BACKGROUND:Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. In 2008, approximately 37,680 people will be diagnosed with pancreatic cancer and 34,290 will die of this disease. METHODS: The authors reviewed the literature on treatment of pancreatic cancer with an emphasis on studies conducted in the US Oncology Research (USOR) Network. RESULTS: Although much research has been conducted to develop improved systemic therapies of pancreatic cancer, gemcitabine as a single agent remains the current standard of care. Combinations with other chemotherapeutic drugs or biological agents have resulted in limited improvement. CONCLUSIONS: Despite aggressive efforts to improve treatment for patients with pancreatic cancer, limited progress has been made. It is hoped that new studies being planned and conducted will improve outcomes for patients with this disease.
Authors: Jean Robert Delpero; Philippe Bachellier; Nicolas Regenet; Yves Patrice Le Treut; François Paye; Nicolas Carrere; Alain Sauvanet; Aurélie Autret; Olivier Turrini; Geneviève Monges-Ranchin; Jean Marie Boher Journal: HPB (Oxford) Date: 2013-03-07 Impact factor: 3.647
Authors: Samira Fegrachi; Marc G Besselink; Hjalmar C van Santvoort; Richard van Hillegersberg; Izaak Quintus Molenaar Journal: HPB (Oxford) Date: 2013-04-18 Impact factor: 3.647
Authors: Anita Koushik; Donna Spiegelman; Demetrius Albanes; Kristin E Anderson; Leslie Bernstein; Piet A van den Brandt; Leif Bergkvist; Dallas R English; Jo L Freudenheim; Charles S Fuchs; Jeanine M Genkinger; Graham G Giles; R Alexandra Goldbohm; Pamela L Horn-Ross; Satu Männistö; Marjorie L McCullough; Amy E Millen; Anthony B Miller; Kim Robien; Thomas E Rohan; Arthur Schatzkin; James M Shikany; Rachael Z Stolzenberg-Solomon; Walter C Willett; Alicja Wolk; Regina G Ziegler; Stephanie A Smith-Warner Journal: Am J Epidemiol Date: 2012-08-08 Impact factor: 4.897
Authors: Donald A Richards; Paul R Kuefler; Carlos Becerra; Lalan S Wilfong; Robert H Gersh; Kristi A Boehm; Feng Zhan; Lina Asmar; Scott P Myrand; Rebecca R Hozak; Luping Zhao; John F Gill; Brian P Mullaney; Coleman K Obasaju; Steven J Nicol Journal: Invest New Drugs Date: 2009-08-28 Impact factor: 3.850